title: Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics.
abstract: BACKGROUND
  Human immunodeficiency virus (HIV) infection has a major but unquantified impact on the risk of tuberculosis.
  
  
  OBJECTIVE
  To quantify the impact of HIV infection on the number of tuberculosis cases in San Francisco.
  
  
  METHODS
  We studied all patients reported with tuberculosis in San Francisco from 1991 to 2002. The initial isolates of Mycobacterium tuberculosis were genotyped using IS6110 restriction fragment-length polymorphism genotyping as the primary method, and clustered cases (identical genotype patterns) were identified.
  
  
  RESULTS
  We determined the case number, case rate, and the fraction of tuberculosis attributable to HIV infection. Of 2,991 reported tuberculosis cases, 2,193 (73.3%) had a genotype pattern of M. tuberculosis available. Genotypic clusters with at least one HIV-positive person were larger, lasted longer, and had a shorter time between successive cases relative to clusters with only HIV-uninfected persons (P < 0.00005, P = 0.0009, P = 0.018, respectively). Overall, 13.7% of the tuberculosis cases were attributable to HIV infection and an estimated 405 excess tuberculosis cases occurred.
  
  
  CONCLUSIONS
  During a period encompassing the resurgence and decline of tuberculosis in San Francisco, a substantial number of the tuberculosis cases were attributable to HIV infection. Coinfection with HIV amplified the local tuberculosis epidemic.
authors: School of Medicine, University of California, Davis, California 95616, USA. kderiemer@ucdavis.edu
authors: Kathryn
authors: K
authors: DeRiemer
authors: L Masae
authors: LM
authors: Kawamura
authors: Philip C
authors: PC
authors: Hopewell
authors: Charles L
authors: CL
authors: Daley
mesh_terms: D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D016022:Case-Control Studies; D016000:Cluster Analysis; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D012495:San Francisco / Q000453:epidemiology; D013997:Time Factors; D014376:Tuberculosis / Q000453:epidemiology* / Q000635:transmission
references: AIDS. 2005 Dec 2;19(18):2109-16
references: 16284460
references: Am J Respir Crit Care Med. 2005 Nov 1;172(9):1169-227
references: 16249321
references: Emerg Infect Dis. 2006 May;12(5):729-35
references: 16704828
references: Am J Respir Crit Care Med. 2007 Jan 1;175(1):87-93
references: 16973982
references: PLoS Med. 2007 Jan;4(1):e22
references: 17199408
references: JAMA. 1995 Jul 12;274(2):143-8
references: 7596002
references: Int J Tuberc Lung Dis. 1999 Nov;3(11):962-75
references: 10587318
references: AIDS. 2000 Jun 16;14(9):1219-28
references: 10894287
references: Clin Infect Dis. 2001 Dec 1;33(11):1922-30
references: 11692305
references: J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):437-44
references: 11744831
references: Am J Respir Crit Care Med. 2001 Dec 15;164(12):2166-71
references: 11751181
references: Clin Infect Dis. 2002 Feb 15;34(4):543-6
references: 11797184
references: Am J Epidemiol. 2002 Mar 15;155(6):565-71
references: 11882530
references: Lancet. 2002 Jun 15;359(9323):2059-64
references: 12086758
references: Bull World Health Organ. 2002;80(12):939-45
references: 12571721
references: Arch Intern Med. 2003 May 12;163(9):1009-21
references: 12742798
references: Science. 2003 Sep 12;301(5639):1535-7
references: 12920302
references: AIDS. 2003 Nov 21;17(17):2501-8
references: 14600522
references: Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S424-31
references: 14677833
references: Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S471-8
references: 14677840
references: AIDS. 2004 Jan 2;18(1):81-8
references: 15090833
references: AIDS. 2004 Jul 2;18(10):1459-63
references: 15199323
references: Am J Respir Crit Care Med. 2004 Sep 15;170(6):673-9
references: 15191919
references: Int J Tuberc Lung Dis. 2004 Sep;8(9):1041-2
references: 15455586
references: N Engl J Med. 1989 Mar 2;320(9):545-50
references: 2915665
references: N Engl J Med. 1992 Jan 23;326(4):231-5
references: 1345800
references: J Clin Microbiol. 1993 Feb;31(2):406-9
references: 8381814
references: J Clin Microbiol. 1993 Jul;31(7):1677-82
references: 8102372
references: JAMA. 1994 Aug 10;272(6):455-61
references: 8040981
references: Tuber Lung Dis. 1995 Apr;76(2):114-21
references: 7780092
references: Am J Med Sci. 1996 Jan;311(1):17-22
references: 8571981
references: J Clin Microbiol. 1996 May;34(5):1118-23
references: 8727887
references: AIDS. 1996 Mar;10(3):269-72
references: 8882666
references: AIDS. 1999 Mar 11;13(4):501-7
references: 10197379
references: Ann Intern Med. 1999 Jun 15;130(12):971-8
references: 10383367
references: Int J Tuberc Lung Dis. 1999 Jun;3(6):457-65
references: 10383056
references: Am J Public Health. 1999 Jul;89(7):1078-82
references: 10394319
references: J Infect Dis. 2005 Jan 15;191(2):150-8
references: 15609223
references: N Engl J Med. 2005 Feb 10;352(6):570-85
references: 15703422
references: N Engl J Med. 2005 Feb 10;352(6):586-95
references: 15703423
references: JAMA. 2005 Jun 8;293(22):2740-5
references: 15941803
references: JAMA. 2005 Jun 8;293(22):2767-75
references: 15941807
references: Nat Rev Immunol. 2005 Oct;5(10):819-26
references: 16200083
references: AIDS. 2006 Apr 4;20(6):915-21
references: 16549977